Konstantinos Sfaelos

Dr. Konstantinos Sfaelos

Department of Skin & Venereal Diseases, University of Ioannina, Ioánnina, Ípeiros, Greece

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
KSKonstantinos Seretis
Konstantinos Seretis
Konstantinos SfaelosKonstantinos Sfaelos
Konstantinos Sfaelos
EBEleni Boptsi
Eleni Boptsi
GGGEORGIOS GAITANIS
GEORGIOS GAITANIS
IBIoannis Bassukas
Ioannis Bassukas
With the ongoing progress of basic research along with the introduction of new pharmaceutical options spanning almost all therapeutic areas, the need for biomarkers that will be implemented into the personalized medical approach is higher than ever. Their use can be incorporated into clinical practice and can be applied to the classification of disorders and the evaluation of disease severity but also to the monitoring of the progress of therapeutic/pharmaceutical interventions. This systematic review collects the findings of hematologic biomarkers in various cutaneous malignancies, excluding malignant melanoma, to support their potential use in the prognosis but also in the assessment of therapeutic strategies for the specific category of skin disorders.

30 May 2022 in Dermatologic Therapy
Verified
Journal Article
Closed access
ETEleftheria Tampouratzi
Eleftheria Tampouratzi
MPMarkos Papakonstantis
Markos Papakonstantis
JKJohn Katsantonis
John Katsantonis
TSTheodoros Sidiropoulos
Theodoros Sidiropoulos
FDFlorentina Delli
Florentina Delli
PPPantelis Panagakis
Pantelis Panagakis

Verified
Journal Article
Open access
PDF file
KSKonstantinos Seretis
Konstantinos Seretis
NBNikolaos Bounas
Nikolaos Bounas
Konstantinos SfaelosKonstantinos Sfaelos
Konstantinos Sfaelos
GGGEORGIOS GAITANIS
GEORGIOS GAITANIS
IBIoannis Bassukas
Ioannis Bassukas
Background/Objectives: Fournier’s Gangrene (FG) is a severe and potentially fatal necrotizing infection of the perianal and genital regions, which necessitates prompt therapeutic interventions to prevent disease progression. Accruing evidence from recent research indicates that the neutrophil‒to-lymphocyte ratio (NLR) can predict clinical severity and mortality risk in patients with critical illnesses across various etiologies. This meta-analysis aimed to assess the efficacy of NLR as a prognostic indicator for mortality in patients with FG. Methods: An electronic literature search was conducted across several databases from their inception to 31 May 2024, following a predetermined protocol. Study quality was evaluated using the Cochrane risk of bias tool. A random-effect model was utilized to synthesize the available data. Results: Twelve studies reporting on 767 patients were included in the meta-analysis. Higher NLR levels at presentation were recorded in non-survivors than in survivors (MD = 4.49 [95% CI: 0.67–8.32]; p = 0.02). A 76% increased mortality risk was detected for patients with an NLR ≥ 8 (1.76 RR [1.35–2.3], p = 0.0001), and the mortality risk was more than twofold greater for patients with an NLR ≥ 10 compared to the remaining patients (RR = 2.31 [1.27–4.21], p = 0.006). All included studies exhibited a moderate to serious risk of bias. Conclusions: This meta-analysis reveals that the NLR represents a promising biomarker that can serve as a prognostic indicator in patients with FG. Future studies should address the establishment of proper disease-specific cutoff values to aid in clinical decision-making.

3 February 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
DRDimitrios Rigopoulos
Dimitrios Rigopoulos
ETEleftheria Tampouratzi
Eleftheria Tampouratzi
CACharalampos Angelakopoulos
Charalampos Angelakopoulos
ZAZoe Apalla
Zoe Apalla
IBIoannis Barkis
Ioannis Barkis
TGthe BrIDGE Study Group
the BrIDGE Study Group

1 September 2022 in European Journal Of Dermatology
Verified
Journal Article
Closed access
PDF file
GSGaryfallia Stefanou
Garyfallia Stefanou
SGStamatis Gregoriou
Stamatis Gregoriou
SKStathis Kontodimas
Stathis Kontodimas
Konstantinos SfaelosKonstantinos Sfaelos
Konstantinos Sfaelos
EVEfstratios Vakirlis
Efstratios Vakirlis
GKGeorgia Kourlaba
Georgia Kourlaba
BackgroundAtopic dermatitis (AD) is a common chronic inflammatory skin disorder. In Greece, there is a lack of data on AD epidemiology.ObjectivesThe objective of the present study was to estimate the self-reported prevalence of AD and the prevalence of moderate/severe AD in the adult population in Greece.Materials & MethodsA nationwide cross-sectional survey with a structured questionnaire was conducted, between June 17(th), 2021 and July 12(th), 2021, using Computer Assisted Telephone Interviewing (CATI) and Computer Assisted web Interviewing (CAWI) data collection methods. Several different self-reported AD definitions, as extracted from the literature, were used. Self-reported moderate/severe atopic dermatitis was estimated using the Patient Oriented Eczema Measure (POEM).ResultsMore than 30,500 persons were invited to participate; among them, 3,001 were recruited for the survey. The 12-month self-reported AD prevalence in Greece ranged from 1.7% to 6.4%, while lifetime prevalence reached 11.4%. At least half of the responders who identified with AD during the last 12 months had moderate to very severe eczema. The multivariate analysis confirmed that age, atopy-related comorbidities (asthma, allergies, and rhinitis), a family history of AD, rhinitis, and asthma were factors that are independently associated with AD, irrespective of the definition used.ConclusionThe 12-month and lifetime prevalence of AD in adults in Greece ranges from 1.7% to 6.4% and 3.7% to 11.4%, respectively. At least half of the adults with AD suffer from moderate-to-severe disease. Our study is a first step in understanding AD epidemiology in Greece and may provide useful insights for healthcare decision makers.

23 August 2022 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
EPEvangelia Papadavid
Evangelia Papadavid
EZEfterpi Zafeiriou
Efterpi Zafeiriou
SGSophia Georgiou
Sophia Georgiou
ARAngeliki-Viktoria Roussaki-Schulze
Angeliki-Viktoria Roussaki-Schulze
TSTheofanis Spiliopoulos
Theofanis Spiliopoulos
ELElisavet Lazaridou
Elisavet Lazaridou
To assess the real-world clinical treatment outcomes with brodalumab in patients with moderate-to-severe plaque psoriasis in Greece.This was a longitudinal, retrospective, real-world analysis of da...